Journal Watch · Proceedings of the National Academy of Sciences (PNAS) · 2026

RNA-binding activity of PHGDH drives amyloid-beta production in a human brain organoid model of sporadic Alzheimer's disease.

These findings define a PHGDH-EIF2AK1-EIF2α-BACE1 axis as a key driver of the earliest amyloid pathology in sAD.

Chen J, Xu M, Xu M et al.Proceedings of the National Academy of Sciences (PNAS)3 min readPharma relevance 50/100

DOI: 10.1073/pnas.2532234123PMID: 41701839Study type: preclinical (animal / model) study

TL;DR

These findings define a PHGDH-EIF2AK1-EIF2α-BACE1 axis as a key driver of the earliest amyloid pathology in sAD.

Key findings

  • Mechanistically, this process requires a specific RNA-binding surface within PHGDH and the <i>EIF2AK1</i> 3'UTR.
  • These findings define a PHGDH-EIF2AK1-EIF2α-BACE1 axis as a key driver of the earliest amyloid pathology in sAD.

What they did

Specifically, PHGDH binds the 3'UTR of <i>EIF2AK1</i> mRNA, enabling the physical interaction between PHGDH and the EIF2AK1 protein. By facilitating the recruitment of EIF2AK1 to its substrate EIF2α, this complex drives EIF2α phosphorylation, thereby selectively promoting the translation of BACE1, the rate-limiting enzyme for Aβ generation. We demonstrate that PHGDH overexpression elevates BACE1 protein and intracellular Aβ in neurons and astrocytes across mouse models and human brain organoids, independent of its canonical enzymatic or transcriptional roles.

Full abstract (original)

Background: Pathological progression in sporadic Alzheimer's disease (sAD) initiates with an early rise in soluble amyloid-β (Aβ), preceding plaque formation and neurodegeneration. However, the molecular event triggering this initial accumulation remains unknown. We report that phosphoglycerate dehydrogenase (PHGDH), a consistent biomarker of prodromal sAD, drives Aβ production through a previously unrecognized RNA-binding function.

What they did: Specifically, PHGDH binds the 3'UTR of <i>EIF2AK1</i> mRNA, enabling the physical interaction between PHGDH and the EIF2AK1 protein. By facilitating the recruitment of EIF2AK1 to its substrate EIF2α, this complex drives EIF2α phosphorylation, thereby selectively promoting the translation of BACE1, the rate-limiting enzyme for Aβ generation. We demonstrate that PHGDH overexpression elevates BACE1 protein and intracellular Aβ in neurons and astrocytes across mouse models and human brain organoids, independent of its canonical enzymatic or transcriptional roles.

Results & conclusions: Mechanistically, this process requires a specific RNA-binding surface within PHGDH and the <i>EIF2AK1</i> 3'UTR. These findings define a PHGDH-EIF2AK1-EIF2α-BACE1 axis as a key driver of the earliest amyloid pathology in sAD.

Abstract © the authors / Proceedings of the National Academy of Sciences (PNAS) (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1073/pnas.2532234123 · PubMed 41701839.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Proceedings of the National Academy of Sciences (PNAS) study find?

These findings define a PHGDH-EIF2AK1-EIF2α-BACE1 axis as a key driver of the earliest amyloid pathology in sAD.

What type of study is this?

It is a preclinical (animal / model) study, published in Proceedings of the National Academy of Sciences (PNAS) in 2026. Specifically, PHGDH binds the 3'UTR of <i>EIF2AK1</i> mRNA, enabling the physical interaction between PHGDH and the EIF2AK1 protein.

Where can I read the original paper?

The original is at the publisher via DOI 10.1073/pnas.2532234123. PubMed ID: 41701839. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Chen J, Xu M, Xu M et al.. RNA-binding activity of PHGDH drives amyloid-beta production in a human brain organoid model of sporadic Alzheimer's disease.. Proceedings of the National Academy of Sciences (PNAS) (2026). DOI: 10.1073/pnas.2532234123.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/rna-binding-activity-of-phgdh-drives-amyloid-beta-production-in-a-human-234123/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides